Mochi Health vs Brello: Insurance, Eligibility, and Cost

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — evidence-based guidance on GLP-1 therapies, weight management, and the genetics behind every metabolic decision. Browse all Peptides & GLP-1 education.

Independent editorial commentary. PlexusDx has no commercial relationship with Mochi Health or Brello, runs no affiliate links, and was not paid to write this.

What separates a Mochi-versus-Brello search from the usual comparison is insurance. Mochi leans on an insurance-support approach; Brello runs a cash-pay compounded model. That single difference reshapes cost, access, and paperwork. Here is a fair-balance look as of April 2026.

A comparison shaped by the insurance question

Most GLP-1 telehealth brands are cash-pay, but the insurance angle changes the calculus. Whether a program tries to route your therapy through coverage affects what you pay out of pocket, how much documentation you handle, and whether branded or compounded products are in play. That framing drives this comparison.

Mochi's insurance-support approach

Mochi Health operates telehealth with insurance support. A licensed provider evaluates the patient, and eligible prescriptions are dispensed as branded FDA-approved GLP-1 products or compounded semaglutide or tirzepatide via a licensed pharmacy. See its official website for current program details, including how its coverage support works.

Brello's cash-pay compounded approach

Brello (Brello Health) runs telehealth paired with a compounding pharmacy on a cash-pay basis, with structure, options, and pricing that vary over time. Consult Brello's own site for current details when you read this. Without an insurance layer, its pricing tends to be more directly visible up front.

What each model means for your wallet

Cash-pay compounded telehealth generally spanned roughly $200 to $700 or more per month across the market in April 2026, covering program fees, medication, and dispensing. Insurance-support models can lower out-of-pocket cost when coverage applies, but approval is never guaranteed and can add steps. Verify current terms and any coverage claims at each brand's own page before enrolling.

The science is in the compound

Coverage does not change pharmacology. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual agonist tirzepatide act on appetite and satiety identically, and the evidence — STEP (NEJM, 2021), SURMOUNT (NEJM, 2022), and SURMOUNT-OSA (NEJM, 2024) — belongs to the molecule, whichever program bills for it.

When coverage helps and when it stalls

Insurance support sounds decisive but behaves unevenly. When a plan covers a branded GLP-1, out-of-pocket cost can fall sharply, yet prior authorizations, step therapy, and denials can stall access for weeks. A cash-pay compounded route trades that uncertainty for a predictable bill. Which path serves you depends less on the brand than on your specific plan. Before assuming either route is cheaper, price out the realistic scenario for your own plan, including any prior-authorization delay, rather than the ideal case a marketing page implies; coverage can be genuinely helpful for some patients and a frustrating dead end for others, and only your own plan details decide which.

Genetics: the layer both skip

Neither an insurance model nor a cash-pay model measures your metabolic baseline. TCF7L2, linked to glucose homeostasis and GLP-1 secretion, joins FTO, GLP1R, and MC4R as pathway-level markers of the terrain a clinician prescribes into. They describe biology, not drug response. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights. PlexusDx also offers the compounds through its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — and the test does not predict response to any specific medication.

Independence note: PlexusDx is not affiliated with Mochi Health or Brello; this is education, not a recommendation.

More reading: GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs, and GLP 1 Hormone.

Editorial disclaimer: This comparison is educational. PlexusDx has no tie to Mochi Health or Brello but sells semaglutide and tirzepatide through its own protocols, so read this as a disclosed viewpoint. The Precision Peptide Genetic Test maps gene-pathway influences and does not predict medication response. Consult a qualified provider before starting any protocol.

Weigh a cash-pay alternative: view the PlexusDx Weight Management Protocols, or begin with the Precision Peptide Genetic Test.

Frequently Asked Questions

Does Mochi or Brello work with insurance?

Mochi Health advertises an insurance-support approach, while Brello runs a cash-pay compounded model. Coverage outcomes depend on your plan, the medication, and medical criteria, and are never guaranteed. Confirm exactly what each program does with insurance on its own site before you enroll.

Is cash-pay compounded GLP-1 cheaper than going through coverage?

It depends on your plan. When insurance covers a branded GLP-1, out-of-pocket cost can drop, but approval and step therapy add friction. Cash-pay compounded programs offer more predictable, visible pricing. Compare the real numbers each model gives you rather than assuming one always wins.

Does genetics factor into insurance or coverage decisions?

No. The Precision Peptide Genetic Test maps pathway-level variants in TCF7L2, FTO, and related genes describing baseline metabolism. It informs your conversation with a provider but plays no role in coverage decisions and never predicts your response to a specific GLP-1 medication.

Continue learning at the PlexusDx Education Hub. Browse all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.